A mesorectal incidentaloma: Rare localization of Castleman disease (Case report).
Castleman disease
fibromatosis
incidentaloma
mesorectal tumor
mesorectum
Journal
Experimental and therapeutic medicine
ISSN: 1792-1015
Titre abrégé: Exp Ther Med
Pays: Greece
ID NLM: 101531947
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
24
05
2021
accepted:
23
06
2021
entrez:
7
3
2022
pubmed:
8
3
2022
medline:
8
3
2022
Statut:
ppublish
Résumé
Incidentalomas are defined as tumors or pseudo-tumoral masses accidentally discovered during clinical and imaging investigations. We present a 51-year-old female patient who presented at the gynecology service for genital bleeding caused by uterine fibromatosis. Computerized pelvic tomography showed an engorged uterus completely deformed by numerous intramural and submucosal nodular structures suggestive of multiple fibroids. Behind the uterus, a well-defined, iodophilic, 49/51 mm diameter, tissue-shaped, nodular mass was identified, with pushing borders into the adjacent fat and showing a mass effect on the rectum against which it retained a demarcation zone. A conclusion of the histopathological examination was made. Histopathological aspects and immunohistochemical tests supported the diagnosis of Castleman disease (CD) variant vascular hyaline variant. The mesorectum is a particularly and extremely rare localization for CD, and preoperative diagnosis is difficult to achieve. The correct surgical attitude in the case of an incidental finding in this localization is the extensive resection that satisfies the presumption of a neoplastic formation.
Identifiants
pubmed: 35251334
doi: 10.3892/etm.2022.11194
pii: ETM-0-0-11194
pmc: PMC8892622
doi:
Types de publication
Case Reports
Langues
eng
Pagination
268Informations de copyright
Copyright © 2020, Spandidos Publications.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Exp Ther Med. 2020 Sep;20(3):2489-2492
pubmed: 32765740
J Clin Med. 2020 Aug 12;9(8):
pubmed: 32806580
Hematol Oncol Clin North Am. 2018 Feb;32(1):89-106
pubmed: 29157622
Cancer Invest. 2005;23(2):191
pubmed: 15813512
Leuk Lymphoma. 2015 May;56(5):1252-60
pubmed: 25120049
Eur J Intern Med. 2010 Apr;21(2):123-6
pubmed: 20206884
Cancer. 1972 Mar;29(3):670-83
pubmed: 4551306
Hematol Oncol Clin North Am. 2018 Feb;32(1):53-64
pubmed: 29157619
Exp Ther Med. 2020 Oct;20(4):3383-3388
pubmed: 32905002
J Pak Med Assoc. 2017 Jun;67(6):917-922
pubmed: 28585593
Hematol Oncol Clin North Am. 2018 Feb;32(1):65-73
pubmed: 29157620
Mod Rheumatol. 2018 Jan;28(1):161-167
pubmed: 28880697
Ann Surg. 2012 Apr;255(4):677-84
pubmed: 22367441
Hematol Oncol Clin North Am. 2018 Feb;32(1):1-10
pubmed: 29157611
Cancer. 1956 Jul-Aug;9(4):822-30
pubmed: 13356266
Chirurgia (Bucur). 2019 Mar-Apr;114(2):234-242
pubmed: 31060656
Cancer Control. 2014 Oct;21(4):266-78
pubmed: 25310208
Chirurgia (Bucur). 2013 Nov-Dec;108(6):886-91
pubmed: 24331331
Blood. 2005 Oct 15;106(8):2627-32
pubmed: 15998837
Br J Radiol. 2010 Apr;83(988):276-89
pubmed: 20335439
Surg Today. 2011 Feb;41(2):271-5
pubmed: 21264768
Korean J Hematol. 2012 Sep;47(3):163-77
pubmed: 23071471
Gastroenterol Rep (Oxf). 2017 Jan 5;7(2):141-145
pubmed: 28057712
BMJ. 2018 Jun 18;361:k2387
pubmed: 29914908
BMJ. 2018 Jun 18;361:k2611
pubmed: 29914864
Clin Adv Hematol Oncol. 2010 Jul;8(7):486-98
pubmed: 20864917
Br J Haematol. 2018 Jan;180(2):206-216
pubmed: 29143319